Nasal-nanotechnology: revolution for efficient therapeutics delivery

References

• Aggarwal R, Cardozo A, Homer JJ. (2004). The assessment of topical nasal drug distribution. Clin Otolaryngol Allied Sci 29:201–5
   PubMed Web of Science ®Google Scholar
• Al-Ghananeem AM, Malkawi AH, Crooks PA. (2011). Bioavailability of Delta(9)-tetrahydrocannabinol following intranasal administration of a mucoadhesive gel spray delivery system in conscious rabbits. Drug Dev Ind Pharm 37:329–34
   PubMed Web of Science ®Google Scholar
• Al-Ghananeem AM, Saeed H, Florence R, et al. (2010). Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by AIDS viruses. J Drug Target 18:381–8
   PubMed Web of Science ®Google Scholar
• Ali J, Ali M, Baboota S, et al. (2010). Potential of nanoparticulate drug delivery systems by intranasal administration. Curr Pharm Des 16:1644–53
   PubMed Web of Science ®Google Scholar
• Almeida AJ, Alpar HO. (1996). Nasal delivery of vaccines. J Drug Target 3:455–67
   PubMed Web of Science ®Google Scholar
• Alsarra IA, Hamed AY, Mahrous GM, et al. (2009). Mucoadhesive polymeric hydrogels for nasal delivery of acyclovir. Drug Dev Ind Pharm 35:352–62
   PubMed Web of Science ®Google Scholar
• Amidi M, Romeijn SG, Verhoef JC, et al. (2007). N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model. Vaccine 25:144–53
   PubMed Web of Science ®Google Scholar
• Arora P, Sharma S, Garg S. (2002). Permeability issues in nasal drug delivery. Drug Discov Today 7:967–75
   PubMed Web of Science ®Google Scholar
• Bacon A, Makin J, Sizer PJ, et al. (2000). Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens. Infect Immun 68:5764–70
   PubMed Web of Science ®Google Scholar
• Bahadur S, Pathak K. (2012a). Buffered nanoemulsion for nose to brain delivery of ziprasidone hydrochloride: preformulation and pharmacodynamic evaluation. Curr Drug Deliv 9:596–607
   PubMed Web of Science ®Google Scholar
• Bahadur S, Pathak K. (2012b). Physicochemical and physiological considerations for efficient nose-to-brain targeting. Expert Opin Drug Deliv 9:19–31
   PubMed Web of Science ®Google Scholar
• Balle VH, Illum P, Meistrup-Larsen U, Olesen KF. (1979). Disodium cromoglycate in the treatment of allergic conditions of the nose. Ugeskr Laeger 141:1906–8
   PubMedGoogle Scholar
• Belgamwar VS, Patel HS, Joshi AS, et al. (2011). Design and development of nasal mucoadhesive microspheres containing tramadol HCl for CNS targeting. Drug Deliv 18:353–60
   PubMed Web of Science ®Google Scholar
• Bielinska AU, Janczak KW, Landers JJ, et al. (2007). Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge. Infect Immun 75:4020–9
   PubMed Web of Science ®Google Scholar
• Bijani C, Arnarez C, Brasselet S, et al. (2012). Stability and structure of protein-lipoamino acid colloidal particles: toward nasal delivery of pharmaceutically active proteins. Langmuir 28:5783–94
   PubMed Web of Science ®Google Scholar
• Bitter C, Suter-Zimmermann K, Surber C. (2011). Nasal drug delivery in humans. Curr Probl Dermatol 40:20–35
   PubMedGoogle Scholar
• Boek WM, Romeijn SG, Graamans K, et al. (1999). Validation of animal experiments on ciliary function in vitro. II. The influence of absorption enhancers, preservatives and physiologic saline. Acta Otolaryngol 119:98–101
   Google Scholar
• Bommer R. (1999). Latest advances in nasal drug-delivery technology. Med Device Technol 10:22–8
   PubMedGoogle Scholar
• Boogaard R, de Jongste JC, Merkus PJ. (2007). Pharmacotherapy of impaired mucociliary clearance in non-CF pediatric lung disease. A review of the literature. Pediatr Pulmonol 42:989–1001
   PubMed Web of Science ®Google Scholar
• Bragagni M, Mennini N, Ghelardini C, Mura P. (2012). Development and characterization of niosomal formulations of doxorubicin aimed at brain targeting. J Pharm Pharm Sci 15:184–96
   PubMed Web of Science ®Google Scholar
• Brave A, Hallengard D, Schroder U, et al. (2008). Intranasal immunization of young mice with a multigene HIV-1 vaccine in combination with the N3 adjuvant induces mucosal and systemic immune responses. Vaccine 26:5075–8
   PubMed Web of Science ®Google Scholar
• Brooking J, Davis SS, Illum L. (2001). Transport of nanoparticles across the rat nasal mucosa. J Drug Target 9:267–79
   PubMed Web of Science ®Google Scholar
• Caban S, Capan Y, Couvreur P, Dalkara T. (2012). Preparation and characterization of biocompatible chitosan nanoparticles for targeted brain delivery of peptides. Methods Mol Biol 846:321–32
   PubMedGoogle Scholar
• Cai Z, Song X, Sun F, et al. (2011). Formulation and evaluation of in situ gelling systems for intranasal administration of gastrodin. AAPS PharmSciTech 12:1102–9
   PubMed Web of Science ®Google Scholar
• Cao SL, Ren XW, Zhang QZ, et al. (2009). In situ gel based on gellan gum as new carrier for nasal administration of mometasone furoate. Int J Pharm 365:109–15
   PubMed Web of Science ®Google Scholar
• Cerchiara T, Luppi B, Chidichimo G, et al. (2005). Chitosan and poly(methyl vinyl ether-co-maleic anhydride) microparticles as nasal sustained delivery systems. Eur J Pharm Biopharm 61:195–200
   PubMed Web of Science ®Google Scholar
• Chandler SG, Thomas NW, Illum L. (1994). Nasal absorption in the rat. III. Effect of lysophospholipids on insulin absorption and nasal histology. Pharm Res 11:1623–30
   PubMed Web of Science ®Google Scholar
• Charlton ST, Davis SS, Illum L. (2007). Nasal administration of an angiotensin antagonist in the rat model: effect of bioadhesive formulations on the distribution of drugs to the systemic and central nervous systems. Int J Pharm 338:94–103
   PubMed Web of Science ®Google Scholar
• Chen J, Zhang C, Liu Q, et al. (2012). Solanum tuberosum lectin-conjugated PLGA nanoparticles for nose-to-brain delivery: in vivo and in vitro evaluations. J Drug Target 20:174–84
   PubMed Web of Science ®Google Scholar
• Chen W, Zhan C, Gu B, et al. (2011). Targeted brain delivery of itraconazole via RVG29 anchored nanoparticles. J Drug Target 19:228–34
   PubMed Web of Science ®Google Scholar
• Chiou CJ, Tseng LP, Deng MC, et al. (2009). Mucoadhesive liposomes for intranasal immunization with an avian influenza virus vaccine in chickens. Biomaterials 30:5862–8
   PubMed Web of Science ®Google Scholar
• Chung SW, Hil-lal TA, Byun Y. (2012). Strategies for non-invasive delivery of biologics. J Drug Target 20:481–501
   PubMed Web of Science ®Google Scholar
• Cokcaliskan C, Ozyoruk F, Gursoy RN, et al. (2014). Chitosan-based systems for intranasal immunization against foot-and-mouth disease. Pharm Dev Technol 19:181–8
   PubMed Web of Science ®Google Scholar
• Costantino HR, Illum L, Brandt G, et al. (2007). Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm 337:1–24
   PubMed Web of Science ®Google Scholar
• Critchley H, Davis SS, Farraj NF, Illum L. (1994). Nasal absorption of desmopressin in rats and sheep. Effect of a bioadhesive microsphere delivery system. J Pharm Pharmacol 46:651–6
   PubMed Web of Science ®Google Scholar
• Cros CD, Toth I, Blanchfield JT. (2011). Lipophilic derivatives of leu-enkephalinamide: in vitro permeability, stability and in vivo nasal delivery. Bioorg Med Chem 19:1528–34
   PubMed Web of Science ®Google Scholar
• Csaba N, Garcia-Fuentes M, Alonso MJ. (2009). Nanoparticles for nasal vaccination. Adv Drug Deliv Rev 61:140–57
   PubMed Web of Science ®Google Scholar
• Davis SS, Illum L. (2003). Absorption enhancers for nasal drug delivery. Clin Pharmacokinet 42:1107–28
   PubMed Web of Science ®Google Scholar
• Deurloo MJ, Hermens WA, Romeyn SG, et al. (1989). Absorption enhancement of intranasally administered insulin by sodium taurodihydrofusidate (STDHF) in rabbits and rats. Pharm Res 6:853–6
   PubMed Web of Science ®Google Scholar
• Djupesland PG, Docekal P. (2010). Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: a randomised, placebo-controlled study. Cephalalgia 30:933–42
   PubMed Web of Science ®Google Scholar
• Djupesland PG, Skretting A, Winderen M, Holand T. (2004). Bi-directional nasal delivery of aerosols can prevent lung deposition. J Aerosol Med 17:249–59
   PubMedGoogle Scholar
• Douglas SJ, Davis SS, Illum L. (1987). Nanoparticles in drug delivery. Crit Rev Ther Drug Carrier Syst 3:233–61
   PubMed Web of Science ®Google Scholar
• Duchateau GS. (1987). Studies on nasal drug delivery. Pharm Weekbl Sci 9:326–8
   PubMedGoogle Scholar
• Duchateau GS, Zuidema J, Merkus FW. (1986a). Bioavailability of propranolol after oral, sublingual, and intranasal administration. Pharm Res 3:108–11
   PubMed Web of Science ®Google Scholar
• Duchateau GS, Zuidema J, Merkus FW. (1986b). The in vitro and in vivo effect of a new non-halogenated corticosteroid – budesonide – aerosol on human ciliary epithelial function. Allergy 41:260–5
   PubMed Web of Science ®Google Scholar
• Duquesnoy C, Mamet JP, Sumner D, Fuseau E. (1998). Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration. Eur J Pharm Sci 6:99–104
   PubMed Web of Science ®Google Scholar
• Elshafeey AH, Bendas ER, Mohamed OH. (2009). Intranasal microemulsion of sildenafil citrate: in vitro evaluation and in vivo pharmacokinetic study in rabbits. AAPS PharmSciTech 10:361–7
   PubMed Web of Science ®Google Scholar
• Eskandari S, Varshosaz J, Minaiyan M, Tabbakhian M. (2011). Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: in vivo pharmacodynamic studies using rat electroshock model. Int J Nanomedicine 6:363–71
   PubMed Web of Science ®Google Scholar
• Eyles JE, Sharp GJ, Williamson ED, et al. (1998a). Intra nasal administration of poly-lactic acid microsphere co-encapsulated Yersinia pestis subunits confers protection from pneumonic plague in the mouse. Vaccine 16:698–707
   PubMed Web of Science ®Google Scholar
• Eyles JE, Spiers ID, Williamson ED, Alpar HO. (1998b). Analysis of local and systemic immunological responses after intra-tracheal, intra-nasal and intra-muscular administration of microsphere co-encapsulated Yersinia pestis sub-unit vaccines. Vaccine 16:2000–9
   PubMed Web of Science ®Google Scholar
• Fazil M, Md S, Haque S, et al. (2012). Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. Eur J Pharm Sci 47:6–15
   PubMed Web of Science ®Google Scholar
• Gaillard PJ, Appeldoorn CC, Rip J, et al. (2012). Enhanced brain delivery of liposomal methylprednisolone improved therapeutic efficacy in a model of neuroinflammation. J Control Release 164:364–9
   PubMed Web of Science ®Google Scholar
• Gavini E, Rassu G, Haukvik T, et al. (2009). Mucoadhesive microspheres for nasal administration of cyclodextrins. J Drug Target 17:168–79
   PubMed Web of Science ®Google Scholar
• Gavini E, Rassu G, Muzzarelli C, et al. (2008). Spray-dried microspheres based on methylpyrrolidinone chitosan as new carrier for nasal administration of metoclopramide. Eur J Pharm Biopharm 68:245–52
   PubMed Web of Science ®Google Scholar
• Gizurarson S. (2012). Anatomical and histological factors affecting intranasal drug and vaccine delivery. Curr Drug Deliv 9:566–82
   PubMed Web of Science ®Google Scholar
• Gizurarson S, Rasmussen SN, Larsen F. (1991). Pharmacokinetics of intranasal drug administration: the influence of some biological factors. J Pharm Sci 80:505–6
   PubMed Web of Science ®Google Scholar
• Greimel A, Bernkop-Schnurch A, Del Curto MD, D'Antonio M. (2007). Transport characteristics of a beta sheet breaker peptide across excised bovine nasal mucosa. Drug Dev Ind Pharm 33:71–7
   PubMed Web of Science ®Google Scholar
• Gungor S, Okyar A, Erturk-Toker S, et al. (2010a). Ondansetron-loaded biodegradable microspheres as a nasal sustained delivery system: in vitro/in vivo studies. Pharm Dev Technol 15:258–65
   PubMed Web of Science ®Google Scholar
• Gungor S, Okyar A, Erturk-Toker S, et al. (2010b). Ondansetron-loaded chitosan microspheres for nasal antiemetic drug delivery: an alternative approach to oral and parenteral routes. Drug Dev Ind Pharm 36:806–13
   PubMed Web of Science ®Google Scholar
• Hafner A, Filipovic-Grcic J, Voinovich D, Jalsenjak I. (2007). Development and in vitro characterization of chitosan-based microspheres for nasal delivery of promethazine. Drug Dev Ind Pharm 33:427–36
   PubMed Web of Science ®Google Scholar
• Hall MA, Stroop SD, Hu MC, et al. (2004). Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections. Infect Immun 72:2507–12
   PubMed Web of Science ®Google Scholar
• Harikarnpakdee S, Lipipun V, Sutanthavibul N, Ritthidej GC. (2006). Spray-dried mucoadhesive microspheres: preparation and transport through nasal cell monolayer. AAPS PharmSciTech 7:E79–88
   PubMed Web of Science ®Google Scholar
• Hasegawa A, Fu Y, Koyama K. (2002). Nasal immunization with diphtheria toxoid conjugated-CD52 core peptide induced specific antibody production in genital tract of female mice. Am J Reprod Immunol 48:305–11
   PubMed Web of Science ®Google Scholar
• He P, Davis SS, Illum L. (1999). Sustained release chitosan microspheres prepared by novel spray drying methods. J Microencapsul 16:343–55
   PubMed Web of Science ®Google Scholar
• Hehar SS, Mason JD, Stephen AB, et al. (1999). Twenty-four hour ambulatory nasal pH monitoring. Clin Otolaryngol Allied Sci 24:24–5
   PubMed Web of Science ®Google Scholar
• Hinchcliffe M, Illum L. (1999). Intranasal insulin delivery and therapy. Adv Drug Deliv Rev 35:199–234
   PubMed Web of Science ®Google Scholar
• Hu KL, Mei N, Feng L, Jiang XG. (2009). Hydrophilic nasal gel of lidocaine hydrochloride. 2nd communication: improved bioavailability and brain delivery in rats with low ciliotoxicity. Arzneimittelforschung 59:635–40
   PubMed Web of Science ®Google Scholar
• Hughes R, Watterson J, Dickens C, et al. (2008). Development of a nasal cast model to test medicinal nasal devices. Proc Inst Mech Eng H 222:1013–22
   PubMed Web of Science ®Google Scholar
• Illum L. (1991). The nasal delivery of peptides and proteins. Trends Biotechnol 9:284–9
   PubMed Web of Science ®Google Scholar
• Illum L. (2000). Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 11:1–18
   PubMed Web of Science ®Google Scholar
• Illum L. (2002). Nasal drug delivery: new developments and strategies. Drug Discov Today 7:1184–9
   PubMed Web of Science ®Google Scholar
• Illum L. (2003). Nasal drug delivery--possibilities, problems and solutions. J Control Release 87:187–98
   PubMed Web of Science ®Google Scholar
• Illum L. (2004). Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol 56:3–17
   PubMed Web of Science ®Google Scholar
• Illum L. (2006). Nasal clearance in health and disease. J Aerosol Med 19:92–9
   PubMedGoogle Scholar
• Illum L. (2007). Nanoparticulate systems for nasal delivery of drugs: a real improvement over simple systems? J Pharm Sci 96:473–83
   PubMed Web of Science ®Google Scholar
• Illum L. (2012). Nasal drug delivery – recent developments and future prospects. J Control Release 161:254–63
   PubMed Web of Science ®Google Scholar
• Illum L, Davis SS. (1991). Drug delivery. Curr Opin Biotechnol 2:254–9
   PubMed Web of Science ®Google Scholar
• Illum L, Davis SS. (2001). Nasal vaccination: a non-invasive vaccine delivery method that holds great promise for the future. Adv Drug Deliv Rev 51:1–3
   PubMed Web of Science ®Google Scholar
• Illum L, Jabbal-Gill I, Hinchcliffe M, et al. (2001). Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev 51:81–96
   PubMed Web of Science ®Google Scholar
• Illum L, Watts P, Fisher AN, et al. (2002). Intranasal delivery of morphine. J Pharmacol Exp Ther 301:391–400
   PubMed Web of Science ®Google Scholar
• Illum P, Balle V. (1978). Immunoglobulins in nasal secretions and nasal mucosa in perennial rhinitis. Acta Otolaryngol 86:135–41
   PubMed Web of Science ®Google Scholar
• Iqbal M, Lin W, Jabbal-Gill I, et al. (2003). Nasal delivery of chitosan-DNA plasmid expressing epitopes of respiratory syncytial virus (RSV) induces protective CTL responses in BALB/c mice. Vaccine 21:1478–85
   PubMed Web of Science ®Google Scholar
• Jain N, Akhter S, Jain GK, et al. (2011). Antiepileptic intranasal Amiloride loaded mucoadhesive nanoemulsion: development and safety assessment. J Biomed Nanotechnol 7:142–3
   PubMed Web of Science ®Google Scholar
• Jain R, Nabar S, Dandekar P, et al. (2010a). Formulation and evaluation of novel micellar nanocarrier for nasal delivery of sumatriptan. Nanomedicine (Lond) 5:575–87
   PubMed Web of Science ®Google Scholar
• Jain R, Nabar S, Dandekar P, Patravale V. (2010b). Micellar nanocarriers: potential nose-to-brain delivery of zolmitriptan as novel migraine therapy. Pharm Res 27:655–64
   PubMed Web of Science ®Google Scholar
• Jayachandra BR, Dayal PP, Pawar K, Singh M. (2011). Nose-to-brain transport of melatonin from polymer gel suspensions: a microdialysis study in rats. J Drug Target 19:731–40
   PubMed Web of Science ®Google Scholar
• Jones N. (2001). The nose and paranasal sinuses physiology and anatomy. Adv Drug Deliv Rev 51:5–19
   PubMed Web of Science ®Google Scholar
• Jones NS, Quraishi S, Mason JD. (1997). The nasal delivery of systemic drugs. Int J Clin Pract 51:308–11
   PubMed Web of Science ®Google Scholar
• Joshi AS, Patel HS, Belgamwar VS, et al. (2012). Solid lipid nanoparticles of ondansetron HCl for intranasal delivery: development, optimization and evaluation. J Mater Sci Mater Med 23:2163–75
   PubMed Web of Science ®Google Scholar
• Jug M, Becirevic-Lacan M. (2008). Development of a cyclodextrin-based nasal delivery system for lorazepam. Drug Dev Ind Pharm 34:817–26
   PubMed Web of Science ®Google Scholar
• Kakkar V, Mishra AK, Chuttani K, et al. (2011). Delivery of sesamol-loaded solid lipid nanoparticles to the brain for menopause-related emotional and cognitive central nervous system derangements. Rejuvenation Res 14:597–604
   PubMed Web of Science ®Google Scholar
• Kang ML, Cho CS, Yoo HS. (2009). Application of chitosan microspheres for nasal delivery of vaccines. Biotechnol Adv 27:857–65
   PubMed Web of Science ®Google Scholar
• Kantar A. (2010). Targeting the nasal cavity in rhinitis and sinusitis. Int J Immunopathol Pharmacol 23:67–9
   PubMedGoogle Scholar
• Karasulu HY, Sanal ZE, Sozer S, et al. (2008). Permeation studies of indomethacin from different emulsions for nasal delivery and their possible anti-inflammatory effects. AAPS PharmSciTech 9:342–8
   PubMed Web of Science ®Google Scholar
• Kim TK, Kang W, Chun IK, et al. (2009). Pharmacokinetic evaluation and modeling of formulated levodopa intranasal delivery systems. Eur J Pharm Sci 38:525–32
   PubMed Web of Science ®Google Scholar
• Kimbell JS, Segal RA, Asgharian B, et al. (2007). Characterization of deposition from nasal spray devices using a computational fluid dynamics model of the human nasal passages. J Aerosol Med 20:59–74
   PubMedGoogle Scholar
• Knuschke T, Sokolova V, Rotan O, et al. (2013). Immunization with biodegradable nanoparticles efficiently induces cellular immunity and protects against influenza virus infection. J Immunol 190:6221–9
   PubMed Web of Science ®Google Scholar
• Kumar A, Sharma P, Chaturvedi A, et al. (2009). Formulation development of sertraline hydrochloride microemulsion for intranasal delivery. Int J ChemTech Res 1:941–7
   Google Scholar
• Kumar M, Misra A, Babbar AK, et al. (2008). Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int J Pharm 358:285–91
   PubMed Web of Science ®Google Scholar
• Kumar R, Dhanawat M, Kumar S, et al. (2014). Carbon nanotubes: a potential concept for drug delivery applications. Recent Pat Drug Deliv Formul 8:12–26
   PubMedGoogle Scholar
• Kundoor V, Dalby RN. (2010). Assessment of nasal spray deposition pattern in a silicone human nose model using a color-based method. Pharm Res 27:30–6
   PubMed Web of Science ®Google Scholar
• Kundu P, Mohanty C, Sahoo SK. (2012). Antiglioma activity of curcumin-loaded lipid nanoparticles and its enhanced bioavailability in brain tissue for effective glioblastoma therapy. Acta Biomater 8:2670–87
   PubMed Web of Science ®Google Scholar
• Laurie E, Hopkins ES, Patchin PC, et al. (2014). Nose-to-brain transport of aerosolized quantum dots following acute exposure. Nanotoxicology 8:885–93
   PubMed Web of Science ®Google Scholar
• Lee KR, Maeng HJ, Chae JB, et al. (2010). Lack of a primary physicochemical determinant in the direct transport of drugs to the brain after nasal administration in rats: potential involvement of transporters in the pathway. Drug Metab Pharmacokinet 25:430–41
   PubMed Web of Science ®Google Scholar
• Lemoine D, Deschuyteneer M, Hogge F, Preat V. (1999). Intranasal immunization against influenza virus using polymeric particles. J Biomater Sci Polym Ed 10:805–25
   PubMed Web of Science ®Google Scholar
• Lifeng Q, Xiaohu G. (2008). Emerging application of quantum dots for drug delivery and therapy. Expert Opin Drug Deliv 5:263–7
   PubMed Web of Science ®Google Scholar
• Lipworth BJ, Jackson CM. (2000). Safety of inhaled and intranasal corticosteroids: lessons for the new millennium. Drug Saf 23:11–33
   PubMed Web of Science ®Google Scholar
• Litvyakova LI, Baraniuk JN. (2001). Nasal provocation testing: a review. Ann Allergy Asthma Immunol 86:355–64
   PubMed Web of Science ®Google Scholar
• Liu Q, Shen Y, Chen J, et al. (2012). Nose-to-brain transport pathways of wheat germ agglutinin conjugated PEG-PLA nanoparticles. Pharm Res 29:546–58
   PubMed Web of Science ®Google Scholar
• Luppi B, Bigucci F, Corace G, et al. (2011). Albumin nanoparticles carrying cyclodextrins for nasal delivery of the anti-Alzheimer drug tacrine. Eur J Pharm Sci 44:559–65
   PubMed Web of Science ®Google Scholar
• Mahajan HS, Tyagi V, Lohiya G, Nerkar P. (2012). Thermally reversible xyloglucan gels as vehicles for nasal drug delivery. Drug Deliv 19:270–6
   PubMed Web of Science ®Google Scholar
• Majithiya RJ, Ghosh PK, Umrethia ML, Murthy RS. (2006). Thermoreversible-mucoadhesive gel for nasal delivery of sumatriptan. AAPS PharmSciTech 7:E80–6
   Web of Science ®Google Scholar
• Makidon PE, Nigavekar SS, Bielinska AU, et al. (2010). Characterization of stability and nasal delivery systems for immunization with nanoemulsion-based vaccines. J Aerosol Med Pulm Drug Deliv 23:77–89
   PubMed Web of Science ®Google Scholar
• Malerba F, Paoletti F, Capsoni S, Cattaneo A. (2011). Intranasal delivery of therapeutic proteins for neurological diseases. Expert Opin Drug Deliv 8:1277–96
   PubMed Web of Science ®Google Scholar
• Marazuela EG, Rodriguez R, Fernandez-Garcia H, et al. (2008). Intranasal immunization with a dominant T-cell epitope peptide of a major allergen of olive pollen prevents mice from sensitization to the whole allergen. Mol Immunol 45:438–45
   PubMed Web of Science ®Google Scholar
• Marttin E, Romeijn SG, Verhoef JC, Merkus FW. (1997). Nasal absorption of dihydroergotamine from liquid and powder formulations in rabbits. J Pharm Sci 86:802–7
   PubMed Web of Science ®Google Scholar
• Marttin E, Verhoef JC, Merkus FW. (1998). Efficacy, safety and mechanism of cyclodextrins as absorption enhancers in nasal delivery of peptide and protein drugs. J Drug Target 6:17–36
   PubMed Web of Science ®Google Scholar
• Mason JD, Aspden TJ, Adler J, et al. (1995). Measurement of nasal mucociliary transport rates on the isolated human inferior turbinate. Clin Otolaryngol Allied Sci 20:530–5
   PubMed Web of Science ®Google Scholar
• McDonough JA, Persyn JT, Nino JA, et al. (2007). Microcapsule-gel formulation of promethazine HCl for controlled nasal delivery: a motion sickness medication. J Microencapsul 24:109–16
   PubMed Web of Science ®Google Scholar
• McNeela EA, Jabbal-Gill I, Illum L, et al. (2004). Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan. Vaccine 22:909–14
   PubMed Web of Science ®Google Scholar
• McNeela EA, O'Connor D, Jabbal-Gill I, et al. (2000). A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. Vaccine 19:1188–98
   PubMed Web of Science ®Google Scholar
• Merkus FW, Schusler-van Hees MT. (1992). Influence of levocabastine suspension on ciliary beat frequency and mucociliary clearance. Allergy 47:230–3
   PubMed Web of Science ®Google Scholar
• Merkus FW, van den Berg MP. (2007). Can nasal drug delivery bypass the blood-brain barrier?: questioning the direct transport theory. Drugs R D 8:133–44
   PubMedGoogle Scholar
• Merkus FW, Verhoef JC, Marttin E, et al. (1999a). Cyclodextrins in nasal drug delivery. Adv Drug Deliv Rev 36:41–57
   PubMed Web of Science ®Google Scholar
• Merkus FW, Verhoef JC, Romeijn SG, Schipper NG. (1991a). Absorption enhancing effect of cyclodextrins on intranasally administered insulin in rats. Pharm Res 8:588–92
   PubMed Web of Science ®Google Scholar
• Merkus FW, Verhoef JC, Romeijn SG, Schipper NG. (1991b). Interspecies differences in the nasal absorption of insulin. Pharm Res 8:1343 (PMID: 1796056)
   PubMed Web of Science ®Google Scholar
• Merkus FW, Verhoef JC, Schipper NG, Marttin E. (1998). Nasal mucociliary clearance as a factor in nasal drug delivery. Adv Drug Deliv Rev 29:13–38
   PubMed Web of Science ®Google Scholar
• Merkus P, Guchelaar HJ, Bosch DA, Merkus FW. (2003). Direct access of drugs to the human brain after intranasal drug administration? Neurology 60:1669–71
   PubMed Web of Science ®Google Scholar
• Merkus P, Romeijn SG, Verhoef JC, et al. (2001). Classification of cilio-inhibiting effects of nasal drugs. Laryngoscope 111:595–602
   PubMed Web of Science ®Google Scholar
• Merkus PJ, de Jongste JC. (2006). Inhaled corticosteroids and long term outcome in adults with asthma. Thorax 61:1011 (PMCID: PMC2121169)
   PubMed Web of Science ®Google Scholar
• Merkus PJ, Hazelzet JA, de Jongste JC. (1999b). Inhalation corticosteroids and the growth of asthmatic children. Ned Tijdschr Geneeskd 143:2547 (PMID: 10627761)
   PubMedGoogle Scholar
• Mistry A, Glud SZ, Kjems J, et al. (2009a). Effect of physicochemical properties on intranasal nanoparticle transit into murine olfactory epithelium. J Drug Target 17:543–52
   PubMed Web of Science ®Google Scholar
• Mistry A, Stolnik S, Illum L. (2009b). Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm 379:146–57
   PubMed Web of Science ®Google Scholar
• Muramatsu K, Maitani Y, Takayama K, Nagai T. (1999). The relationship between the rigidity of the liposomal membrane and the absorption of insulin after nasal administration of liposomes modified with an enhancer containing insulin in rabbits. Drug Dev Ind Pharm 25:1099–105
   PubMed Web of Science ®Google Scholar
• Myc A, Kukowska-Latallo JF, Bielinska AU, et al. (2003). Development of immune response that protects mice from viral pneumonitis after a single intranasal immunization with influenza A virus and nanoemulsion. Vaccine 21:3801–14
   PubMed Web of Science ®Google Scholar
• Nakamura K, Maitani Y, Lowman AM, et al. (1999). Uptake and release of budesonide from mucoadhesive, pH-sensitive copolymers and their application to nasal delivery. J Control Release 61:329–35
   PubMed Web of Science ®Google Scholar
• Nazar H, Fatouros DG, van der Merwe SM, et al. (2011). Thermosensitive hydrogels for nasal drug delivery: the formulation and characterisation of systems based on N-trimethyl chitosan chloride. Eur J Pharm Biopharm 77:225–32
   PubMed Web of Science ®Google Scholar
• Ohwaki T, Ando H, Watanabe S, Miyake Y. (1985). Effects of dose, pH, and osmolarity on nasal absorption of secretin in rats. J Pharm Sci 74:550–2
   PubMed Web of Science ®Google Scholar
• Ozsoy Y, Gungor S, Cevher E. (2009). Nasal delivery of high molecular weight drugs. Molecules 14:3754–79
   PubMed Web of Science ®Google Scholar
• Patel GB, Ponce A, Zhou H, Chen W. (2008). Structural characterization of archaeal lipid mucosal vaccine adjuvant and delivery (AMVAD) formulations prepared by different protocols and their efficacy upon intranasal immunization of mice. J Liposome Res 18:127–43
   PubMed Web of Science ®Google Scholar
• Patel S, Chavhan S, Soni H, et al. (2011). Brain targeting of risperidone-loaded solid lipid nanoparticles by intranasal route. J Drug Target 19:468–74
   PubMed Web of Science ®Google Scholar
• Patil SB, Kaul A, Babbar A, et al. (2012). In vivo evaluation of alginate microspheres of carvedilol for nasal delivery. J Biomed Mater Res B Appl Biomater 100:249–55
   PubMed Web of Science ®Google Scholar
• Patil SB, Sawant KK. (2011). Chitosan microspheres as a delivery system for nasal insufflation. Colloids Surf B Biointerfaces 84:384–9
   PubMed Web of Science ®Google Scholar
• Pires A, Fortuna A, Alves G, Falcao A. (2009). Intranasal drug delivery: how, why and what for? J Pharm Pharm Sci 12:288–311
   PubMed Web of Science ®Google Scholar
• Pisal PB, Patil SS, Pokharkar VB. (2012). Rheological investigation and its correlation with permeability coefficient of drug loaded carbopol gel: influence of absorption enhancers. Drug Dev Ind Pharm 39:593–9
   PubMed Web of Science ®Google Scholar
• Pisal S, Shelke V, Mahadik K, Kadam S. (2004a). Effect of organogel components on in vitro nasal delivery of propranolol hydrochloride. AAPS PharmSciTech 5:92–100
   Web of Science ®Google Scholar
• Pisal SS, Paradkar AR, Mahadik KR, Kadam SS. (2004b). Pluronic gels for nasal delivery of Vitamin B12. Part I: preformulation study. Int J Pharm 270:37–45
   PubMed Web of Science ®Google Scholar
• Quraishi MS, Jones NS, Mason JD. (1997). The nasal delivery of drugs. Clin Otolaryngol Allied Sci 22:289–301
   PubMed Web of Science ®Google Scholar
• Rajadhyaksha M, Boyden T, Liras J, et al. (2011). Current advances in delivery of biotherapeutics across the blood-brain barrier. Curr Drug Discov Technol 8:87–101
   PubMedGoogle Scholar
• Read RC, Naylor SC, Potter CW, et al. (2005). Effective nasal influenza vaccine delivery using chitosan. Vaccine 23:4367–74
   PubMed Web of Science ®Google Scholar
• Ruan Y, Yao L, Zhang B, et al. (2011). Antinociceptive properties of nasal delivery of neurotoxin-loaded nanoparticles coated with polysorbate-80. Peptides 32:1526–9
   PubMed Web of Science ®Google Scholar
• Salama HA, Mahmoud AA, Kamel AO, et al. (2012). Brain delivery of olanzapine by intranasal administration of transfersomal vesicles. J Liposome Res 22:336–45
   PubMed Web of Science ®Google Scholar
• Scheerlinck JP, Gekas S, Yen HH, et al. (2006). Local immune responses following nasal delivery of an adjuvanted influenza vaccine. Vaccine 24:3929–36
   PubMed Web of Science ®Google Scholar
• Schipper NG, Romeijn SG, Verhoef J, Merkus FW. (1994). Hypocalcemic effect of salmon calcitonin following single and repeated nasal and intravenous administration in young rabbits. Calcif Tissue Int 54:50–5
   PubMed Web of Science ®Google Scholar
• Schipper NG, Verhoef JC, Merkus FW. (1991). The nasal mucociliary clearance: relevance to nasal drug delivery. Pharm Res 8:807–14
   PubMed Web of Science ®Google Scholar
• Seju U, Kumar A, Sawant KK. (2011). Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: in vitro and in vivo studies. Acta Biomater 7:4169–76
   PubMed Web of Science ®Google Scholar
• Shahiwala A, Misra A. (2004). Nasal delivery of levonorgestrel for contraception: an experimental study in rats. Fertil Steril 81:893–8
   PubMed Web of Science ®Google Scholar
• Shahiwala A, Misra A. (2006). Preliminary investigation of the nasal delivery of liposomal leuprorelin acetate for contraception in rats. J Pharm Pharmacol 58:19–26
   PubMed Web of Science ®Google Scholar
• Slomkowski S, Gosecki M. (2011). Progress in nanoparticulate systems for peptide, proteins and nucleic acid drug delivery. Curr Pharm Biotechnol 12:1823–39
   PubMed Web of Science ®Google Scholar
• Slot WB, Merkus FW, Van Deventer SJ, Tytgat GN. (1997). Normalization of plasma vitamin B12 concentration by intranasal hydroxocobalamin in vitamin B12-deficient patients. Gastroenterology 113:430–3
   PubMed Web of Science ®Google Scholar
• Smith JH, Papania M, Knaus D, et al. (2012). Nebulized live-attenuated influenza vaccine provides protection in ferrets at a reduced dose. Vaccine 30:3026–33
   PubMed Web of Science ®Google Scholar
• Soane RJ, Carney AS, Jones NS, et al. (2001). The effect of the nasal cycle on mucociliary clearance. Clin Otolaryngol Allied Sci 26:9–15
   PubMed Web of Science ®Google Scholar
• Suman JD. (2003). Nasal drug delivery. Expert Opin Biol Ther 3:519–23
   PubMed Web of Science ®Google Scholar
• Tafaghodi M, Abolghasem Sajadi TS, Jaafari MR, et al. (2004). Evaluation of the clearance characteristics of various microspheres in the human nose by gamma-scintigraphy. Int J Pharm 280:125–35
   PubMed Web of Science ®Google Scholar
• Tafaghodi M, Jaafari MR, Tabassi SA. (2008). Nasal immunization studies by cationic, fusogenic and cationic-fusogenic liposomes encapsulated with tetanus toxoid. Curr Drug Deliv 5:108–13
   PubMedGoogle Scholar
• Tas C, Ozkan CK, Savaser A, et al. (2006). Nasal absorption of metoclopramide from different Carbopol 981 based formulations: in vitro, ex vivo and in vivo evaluation. Eur J Pharm Biopharm 64:246–54
   PubMed Web of Science ®Google Scholar
• Teijeiro-Osorio D, Remunan-Lopez C, Alonso MJ. (2009). New generation of hybrid poly/oligosaccharide nanoparticles as carriers for the nasal delivery of macromolecules. Biomacromolecules 10:243–9
   PubMed Web of Science ®Google Scholar
• van Asselt DZ, Merkus FW, Russel FG, Hoefnagels WH. (1998). Nasal absorption of hydroxocobalamin in healthy elderly adults. Br J Clin Pharmacol 45:83–6
   PubMed Web of Science ®Google Scholar
• van der Kuy PH, Lohman JJ, Hooymans PM, et al. (1999). Bioavailability of intranasal formulations of dihydroergotamine. Eur J Clin Pharmacol 55:677–80
   PubMed Web of Science ®Google Scholar
• Varshosaz J, Sadrai H, Heidari A. (2006). Nasal delivery of insulin using bioadhesive chitosan gels. Drug Deliv 13:31–8
   PubMed Web of Science ®Google Scholar
• Veronesi MC, Kubek DJ, Kubek MJ. (2011). Intranasal delivery of neuropeptides. Methods Mol Biol 789:303–12
   PubMedGoogle Scholar
• Visor GC, Bajka E, Benjamin E. (1986). Intranasal delivery of nicardipine in the rat. J Pharm Sci 75:44–6
   PubMed Web of Science ®Google Scholar
• Vujanic A, Sutton P, Snibson KJ, et al. (2012). Mucosal vaccination: lung versus nose. Vet Immunol Immunopathol 148:172–7
   PubMed Web of Science ®Google Scholar
• Wang D, Christopher ME, Nagata LP, et al. (2004). Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses. J Clin Virol 31:S99–106
   PubMed Web of Science ®Google Scholar
• Wang J, Tabata Y, Morimoto K. (2006). Aminated gelatin microspheres as a nasal delivery system for peptide drugs: evaluation of in vitro release and in vivo insulin absorption in rats. J Control Release 113:31–7
   PubMed Web of Science ®Google Scholar
• Wang SH, Fan Y, Makidon PE, et al. (2012a). Induction of immune tolerance in mice with a novel mucosal nanoemulsion adjuvant and self-antigen. Nanomedicine (Lond) 7:867–76
   PubMed Web of Science ®Google Scholar
• Wang SH, Kirwan SM, Abraham SN, et al. (2012b). Stable dry powder formulation for nasal delivery of anthrax vaccine. J Pharm Sci 101:31–47
   PubMed Web of Science ®Google Scholar
• Wang X, Zheng C, Wu Z, et al. (2009). Chitosan-NAC nanoparticles as a vehicle for nasal absorption enhancement of insulin. J Biomed Mater Res B Appl Biomater 88:150–61
   PubMed Web of Science ®Google Scholar
• Wearley LL. (1991). Recent progress in protein and peptide delivery by noninvasive routes. Crit Rev Ther Drug Carrier Syst 8:331–94
   PubMed Web of Science ®Google Scholar
• Wen Z, Yan Z, He R, et al. (2011). Brain targeting and toxicity study of odorranalectin-conjugated nanoparticles following intranasal administration. Drug Deliv 18:555–61
   PubMed Web of Science ®Google Scholar
• Witschi C, Mrsny RJ. (1999). In vitro evaluation of microparticles and polymer gels for use as nasal platforms for protein delivery. Pharm Res 16:382–90
   PubMed Web of Science ®Google Scholar
• Wu H, Li J, Zhang Q, et al. (2012). A novel small Odorranalectin-bearing cubosomes: preparation, brain delivery and pharmacodynamic study on amyloid-beta(2)(5)(-)(3)(5)-treated rats following intranasal administration. Eur J Pharm Biopharm 80:368–78
   PubMed Web of Science ®Google Scholar
• Xu W, Shen Y, Jiang Z, et al. (2004). Intranasal delivery of chitosan-DNA vaccine generates mucosal SIgA and anti-CVB3 protection. Vaccine 22:3603–12
   PubMed Web of Science ®Google Scholar
• Yang ZZ, Zhang YQ, Wu K, et al. (2012). Tissue distribution and pharmacodynamics of rivastigmine after intranasal and intravenous administration in rats. Curr Alzheimer Res 9:315–25
   PubMed Web of Science ®Google Scholar
• Zhang X, Wang Y, Zheng C, Li C. (2012). Phenylboronic acid-functionalized glycopolymeric nanoparticles for biomacromolecules delivery across nasal respiratory. Eur J Pharm Biopharm 82:76–84
   PubMed Web of Science ®Google Scholar